New York, USA, Jan. 23, 2023 (GLOBE NEWSWIRE) — Primary Biliary Cirrhosis Clinical Trial Pipeline Insights Featuring 22+ Companies | DelveInsight
Primary biliary cholangitis, previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed. Rising healthcare expenditure is one such factor that has influenced the growth rate of PBC. An increase in the number of research and development activities has also led Pharmaceutical companies to develop novel therapies for the treatment of PBC.
DelveInsight’s ‘Primary Biliary Cirrhosis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline primary biliary cirrhosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the primary biliary cirrhosis pipeline domain.
Key Takeaways from the Primary Biliary Cirrhosis Pipeline Report
- DelveInsight’s primary biliary cirrhosis pipeline report depicts a robust space with 22+ active players working to develop 24+ pipeline therapies for primary biliary cirrhosis treatment.
- Key primary biliary cirrhosis companies such as Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals, and others are evaluating new primary biliary cirrhosis drugs to improve the treatment landscape.
- Promising primary biliary cirrhosis pipeline therapies such as Elafibranor, Seladelpar, Setanaxib, Bilypsa, CNP-104, ASC42, Volixibat, Bezafibrate, HTD1801, OP-724, A3907, PDC-E2, HM15211, Pemafibrate, Emtricitabine/Tenofovir Disoproxil/Raltegravir, Research program, Pemafibrate, and others are under different phases of primary biliary cirrhosis clinical trials.
- In November 2022, CymaBay Therapeutics, Inc. announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that were presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC (November 4th – 8th). A clinical poster presentation titled “Seladelpar Improved the Lipid Profile of Patients with Primary Biliary Cholangitis (PBC): Results from Phase 2 and 3 Clinical Studies” reported positive results and showed that treatment with seladelpar resulted in significant improvements in total cholesterol (TC), LDL-C, HDL-C, and triglycerides (TG). A second poster presenting clinical data titled “Seladelpar, a PPAR-delta Agonist, Improves Inflammatory Lipid Mediators in the Serum Metabolome in Patients with Primary Biliary Cholangitis (PBC)” revealed that seladelpar treatment in patients with PBC resulted in broad changes in serum metabolomics.
- In August 2022, Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced that it had finished its first dosing in the US drug-drug interaction (DDI) study of Farnesoid X Receptor agonist ASC42 for treatment of PBC. The DDI study and ongoing phase II clinical trial in PBC patients in China will provide more evidence to support upcoming phase III trials in the US, China, and the European Union.
- GENFIT is currently evaluating its proprietary drug candidate, elafibranor, a dual agonist of PPARα and PPARδ in PBC. Enrollment is ongoing for the Phase III clinical trial ELATIVE (NCT04526665), which aims to confirm elafibranor 80mg efficacy, based upon changes in biochemical parameters and its potential to improve pruritus, and safety in patients with PBC. Elafibranor was granted Breakthrough Therapy designation by the FDA in April 2019 for the treatment of PBC in adults with inadequate response to UDCA, as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency) in July 2019. In November 2022, Genfir announced that Phase III data for elafibranor in primary biliary cholangitis (PBC) is expected in 2Q23.
- CNP-104 is being developed utilizing Cour’s nanoparticle platform (CNP), a novel, proprietary system which combines disease-specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying cells from the body. Cour’s platform has shown proof of technology in clinical and preclinical settings. COUR is currently conducting a clinical study with top-line data expected to read out in 2023. In January 2022, the US Food and Drug Administration (FDA) granted Fast Track designation to CNP-104 for the treatment of primary biliary cholangitis (PBC).
Request a sample and discover the recent advances in primary biliary cirrhosis treatment drugs @ Primary Biliary Cirrhosis Pipeline Report
The primary biliary cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage primary biliary cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the primary biliary cirrhosis clinical trial landscape.
Primary Biliary Cirrhosis Overview
Primary biliary cirrhosis (PBC) is an autoimmune-related chronic and slowly progressive cholestatic liver disease characterized by intrahepatic bile duct injury that can lead to liver failure. At the time of primary biliary cirrhosis diagnosis, most patients are in their fifth to seventh decades of life, and 90% are female.
PBC does not always cause symptoms, but some people may experience bone and joint aches, fatigue (extreme tiredness), itchy skin, dry eyes and mouth, and pain or discomfort in their upper right tummy. Most patients are asymptomatic at the time of diagnosis; however, some patients present with fatigue and pruritus.
A combination of clinical features, an abnormal liver biochemical pattern in a cholestatic picture that persists for more than six months, and the presence of detectable antimitochondrial antibodies (AMA) in serum are used to make the primary biliary cirrhosis diagnosis.
Find out more about primary biliary cirrhosis treatment drugs @ Drugs for Primary Biliary Cirrhosis Treatment
A snapshot of the Primary Biliary Cirrhosis Pipeline Drugs mentioned in the report:
|Elafibranor||Genfit||Phase III||Antioxidants; Peroxisome proliferator-activated receptor alpha agonists||Oral|
|Seladelpar||CymaBay Therapeutics||Phase III||C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists||Oral|
|Bezafibrate/obeticholic acid||Intercept Pharmaceuticals||Phase II||Farnesoid X-activated receptor agonists; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists||Oral|
|CNP-104||Cour Pharmaceutical||Phase II||Immunomodulators||Intravenous|
|ASC42||Gannex Pharma||Phase II||Farnesoid X-activated receptor agonists; Hepatitis B surface antigen expression inhibitors; RNA inhibitors||Oral|
|OP-724||Ohara Pharmaceutical||Phase I||Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors||Intravenous|
Learn more about the emerging primary biliary cirrhosis pipeline therapies @ Primary Biliary Cirrhosis Clinical Trials
Primary Biliary Cirrhosis Therapeutics Assessment
The primary biliary cirrhosis pipeline report proffers an integral view of the primary biliary cirrhosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Primary Biliary Cirrhosis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: Antioxidants; C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists, Farnesoid X-activated receptor agonists; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists, Immunomodulators, Farnesoid X-activated receptor agonists; Hepatitis B surface antigen expression inhibitors; RNA inhibitors, Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
- Key Primary Biliary Cirrhosis Companies: Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals and others
- Key Primary Biliary Cirrhosis Pipeline Therapies: Elafibranor, Seladelpar, Setanaxib, Bilypsa, CNP-104, ASC42, Volixibat, Bezafibrate, HTD1801, OP-724, A3907, PDC-E2, HM15211, Pemafibrate, Emtricitabine/Tenofovir Disoproxil/Raltegravir, Research program, Pemafibrate and others
Dive deep into rich insights for new drugs for primary biliary cirrhosis treatment, visit @ Primary Biliary Cirrhosis Drugs
Table of Contents
|1.||Primary Biliary Cirrhosis Pipeline Report Introduction|
|2.||Primary Biliary Cirrhosis Pipeline Report Executive Summary|
|3.||Primary Biliary Cirrhosis Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Primary Biliary Cirrhosis Clinical Trial Therapeutics|
|6.||Primary Biliary Cirrhosis Pipeline: Late Stage Products (Pre-registration)|
|7.||Primary Biliary Cirrhosis Pipeline: Late Stage Products (Phase III)|
|8.||Primary Biliary Cirrhosis Pipeline: Mid Stage Products (Phase II)|
|8.1||CNP-104: Cour Pharmaceutical|
|9.||Primary Biliary Cirrhosis Pipeline: Early Stage Products (Phase I)|
|9.1||OP-724: Ohara Pharmaceutical|
|10.||Primary Biliary Cirrhosis Pipeline Therapeutics Assessment|
|11.||Inactive Products in the Primary Biliary Cirrhosis Pipeline|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|14.||Key Products in the Primary Biliary Cirrhosis Pipeline|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
For further information on the primary biliary cirrhosis pipeline therapeutics, reach out @ Primary Biliary Cirrhosis Treatment Drugs
Primary Biliary Cirrhosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted primary biliary cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary biliary cirrhosis companies, including Cour Pharmaceutical Development, Ascletis, Novartis, Mirum Pharmaceuticals, Intercept Pharmaceuticals, among others.
Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary sclerosing cholangitis companies, including Mirum Pharmaceuticals, Chemomab Therapeutics, Cascade Pharmaceuticals, among others.
Primary Sclerosing Cholangitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary sclerosing cholangitis companies, including Mirum Pharmaceuticals, Chemomab Therapeutics, Cascade Pharmaceuticals, among others.
Primary Sclerosing Cholangitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted primary sclerosing cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nonalcoholic Steatohepatitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, Cirius Therapeutics, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Cisco Doubles Down on Network Assurance with AWS
Cisco delivers seamless integration between ThousandEyes and Amazon CloudWatch Internet Monitor.ThousandEyes’ unmatched cloud and Internet visibility combined with AWS’s Internet health and performance insights will allow a complete view of an application’s entire service delivery path, across private environments, the public Internet and into AWS’s network.Customers benefit from new operational insights and recommendations enabling them to optimize deployments and assure exceptional digital experiences for any AWS-hosted application.LAS VEGAS, Nov. 28, 2023 /PRNewswire/ — AWS re:Invent — Today at AWS re:Invent 2023, Cisco (NASDAQ: CSCO) announced new integrations between Cisco ThousandEyes and Amazon CloudWatch Internet Monitor (CWIM), a new Internet monitoring service from Amazon Web Services (AWS). The first-of-its-kind integration empowers customers with unparalleled visibility into their cloud deployments, enabling them to deliver unmatched optimized digital experiences.
With this new integration, customers can leverage operational insights to ensure optimal placement of AWS instances and monitoring coverage based on user traffic profiles. This integration comes on the heels of ThousandEyes announcing AWS Network Path Enrichment, giving customers deeper visibility into AWS by enriching ThousandEyes Path Visualization with data from AWS data sources—helping customers work more collaboratively with providers to resolve issues that are impacting application performance.
Building upon the existing relationship between AWS and Cisco, the new integration demonstrates Cisco’s deep commitment to its end-to-end network assurance vision. Cisco securely and sustainably connects everyone to everything and assures the digital experience of every one of those connections. By working with AWS, Cisco is delivering on its promise to provide visibility into every domain that impacts digital experience—whether user, enterprise, Internet, or cloud—so it can ultimately provide artificial intelligence (AI)-driven insights, recommendations, and remediations to support the digital transformation of every customer, wherever they are on their journey.
“Since launching one year ago, Amazon CloudWatch Internet Monitor has delivered real-time insights into the traffic and performance of our customers’ AWS VPCs, CloudFront distributions, and Workspaces towards Internet destinations. In-depth Internet visibility is critical to our customers, so we’re excited to combine forces with ThousandEyes to provide a comprehensive view of Internet health.” — Robert Kennedy, VP of AWS Border Network Engineering, AWS
“Connectivity is key to Sutherland’s business model and to our customer interactions. Cloud visibility is a big part of that and with ThousandEyes’ end-to-end visibility all the way from our employees’ home environments to AWS, we’re able to quickly catch and resolve issues which allows us to deliver consistent high-quality application experiences to both our employees and customers.”—Ted Sanfilippo, VP Infrastructure, Head of Global Network Services and GTOC, Sutherland
“Customers today need to assure digital experiences over any network—the ones they own and the ones they don’t. As the leader in Internet visibility, Cisco is on a mission to deliver unmatched, end-to-end network assurance. Today’s integration with AWS demonstrates our shared commitment to empower our customers to more effectively monitor and manage their cloud environments.”— Mohit Lad, Senior Vice President and General Manager, Network Assurance, Cisco, and Co-Founder, ThousandEyes
For more information and live demos visit ThousandEyes at AWS re:Invent at booth #1621. Join our Lightning Talk on the exhibit floor: NET102-S, “Extending ThousandEyes visibility to the AWS network,” November 28 at 3:30 PM – 3:50 PM (PDT)
The Amazon CloudWatch Internet Monitor integration will be available in Cisco ThousandEyes in spring 2024. The ThousandEyes platform is available for purchase today in AWS Marketplace.Additional Resources
ThousandEyes Announcement BlogAWS Marketplace: CiscoCisco at AWS re:Invent 2023Additional Cisco news at AWS re:InventAbout CiscoCisco (NASDAQ: CSCO) is the worldwide technology leader that securely connects everything to make anything possible. Our purpose is to power an inclusive future for all by helping our customers reimagine their applications, power hybrid work, secure their enterprise, transform their infrastructure, and meet their sustainability goals. Discover more on The Newsroom and follow us on X at @Cisco. Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco’s trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.
Logo – https://mma.prnewswire.com/media/813707/Cisco_v2_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cisco-doubles-down-on-network-assurance-with-aws-301998679.html
Artificial Neural Network Market to Reach $1.4 Billion by 2032 at 19.9% CAGR: Allied Market Research
The growing demand for AI-based solutions and the rising need for intelligent business processes are expected to drive the global artificial neural network market growth.
NEW CASTLE, Del., Nov. 28, 2023 /PRNewswire/ — Allied Market Research published a report, titled, “Artificial Neural Network Market by Component (Solution and Service), Deployment Mode (On-premise and Cloud), Enterprise Size (Large Enterprises and Small & Medium-sized Enterprises), and Industry (Healthcare, BFSI, Retail and E-commerce, Manufacturing, Automotive, and Others): Global Opportunity Analysis and Industry Forecast, 2022–2032”. According to the report, the artificial neural network industry generated $227.8 million in 2022 and is anticipated to generate $1.4 billion by 2032, witnessing a CAGR of 19.9% from 2023 to 2032.
Prime determinants of growth
The notable factors positively affecting the artificial neural network market include the growing demand for AI-based solutions and the rising need for intelligent business processes. However, a lack of computational resources and a skilled workforce with expertise in artificial neural network (ANN) can hinder market growth. Furthermore, advancements in big data analytics and the availability of high-performance computing systems offer lucrative market opportunities for the market players.
Download Sample Pages: https://www.alliedmarketresearch.com/request-sample/13364
Report coverage & details:
Market Size in 2022
Market Size in 2032
No. of Pages in Report
Component, Deployment Mode, Enterprise Size Industry, and Region.
Growing demand for AI-based solutions
The rising need for intelligent business processes
Advancements in big data analytics.
The availability of high-performance computing systems.
A lack of computational resources and a skilled workforce with expertise in artificial neural network (ANN)
Buy this Complete Report (450 Pages PDF with Insights, Charts, Tables, and Figures) at:
The solution segment to maintain its leadership status throughout the forecast period
Based on component, the solution segment held the highest market share in 2022, accounting for less than two-fifths of the artificial neural network market revenue, and is estimated to maintain its leadership status throughout the forecast period. This is attributed to the growing need for a high level of personalization which is one of the primary reasons enterprises are increasing their investment in the artificial neural network market. However, the services segment is projected to manifest the highest CAGR of 21.8% from 2023 to 2032. The services segment is expected to witness the highest growth, as these services help to reduce the time and costs associated with optimizing systems in the initial phase of deployment.
The on-premise segment to maintain its lead position during the forecast period
Based on deployment mode, the on-premise segment accounted for the largest share in 2022, contributing for more than one-fourth of the artificial neural network market revenue. An increase in the need for secure and reliable data within the organization is fueling the market growth for on-premises-based artificial neural network solutions. However, the cloud segment is expected to portray the largest CAGR of 21.2% from 2023 to 2032 and is projected to maintain its lead position during the forecast period. It provides several advantages such as reducing costs, supporting business, and effectively controlling the business environment in the organization.
The large enterprises segment to maintain its lead position during the forecast period
Based on enterprise size, the large enterprises segment accounted for the largest share in 2022, contributing for more than one-fourth of the artificial neural network market revenue, owing to the growing demand for artificial neural network solutions in large enterprises which is fueling the market growth in these enterprises. However, the small and medium-sized enterprises segment is expected to portray the largest CAGR of 22.2% from 2023 to 2032 and is projected to maintain its lead position during the forecast period. It provides various benefits to the small and medium-sized enterprises organization.
The healthcare segment to maintain its lead position during the forecast period
Based on industry vertical, the healthcare segment accounted for the largest share in 2022, contributing for less than two-fifths of the artificial neural network market revenue, owing to the development of digital technologies in IT sector. However, the manufacturing segment is projected to manifest the highest CAGR of 24.3% from 2023 to 2032. The surge in implementation of automation trends and the increase in utilization of digital technology in this sector are expected to provide lucrative opportunities for the market.
North America region dominated the global artificial neural network market in 2022
Based on region, the North America segment held the highest market share in terms of revenue in 2022, accounting for less than two-fifths of the artificial neural network market revenue. The increase in the usage of artificial neural network solutions in businesses to improve businesses and the customer experience is anticipated to propel the growth of the market in this region. However, the Asia-Pacific segment is projected to manifest the highest CAGR of 21.8% from 2023 to 2032. Countries such as China, India, and South Korea are at the forefront, embracing digital technologies to enhance their effectiveness and competitiveness, which is further expected to contribute to the growth of the market in this region.
Enquiry Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/13364
Recent Product launches in the Artificial Neural Network Market
In April 2023, Google LLC launched a cloud-based automation toolkit for healthcare organizations and previewed Med-PaLM 2, a neural network capable of answering medical exam questions.In August 2021, IBM Corporation unveiled details of the upcoming new IBM Telum Processor designed to bring deep learning inference to enterprise workloads to help address fraud in real-time..Recent Partnerships in the Artificial Neural Network Market
In June 2023, Snowflake partnered with Microsoft to simplify joint customers’ artificial intelligence projects. A core focus of the collaboration is Microsoft’s Azure OpenAI Service. It provides cloud-based versions of OpenAI LP’s machine learning models, including GPT-4.In November 2021, Qualcomm Technologies partnered with Google Cloud, on Neural Architecture Search (NAS), enabling the companies to create and optimize AI models automatically rather than manually.Leading Market Players: –
Amazon Web Services Inc. Google Inc. Hewlett Packard Enterprise Development LP IBM Corporation Intel Corporation Microsoft Corporation NVIDIA Corporation Oracle Corporation Qualcomm Technologies Inc. Salesforce Inc.The report provides a detailed analysis of these key players in the artificial neural network market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different countries. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
Trending Reports in ICT & Media Industry:
Network Equipment Market Size is Expected to Reach $69.7 Billion by 2032
Multi-access Edge Computing Market Expected to Reach $102 Billion by 2032
Cloud Native Technologies Market Expected to Reach $53.6 Billion by 2032
Online Language Learning Platform Market Expected to Reach $44.8 Billion by 2032
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports Insights” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Int’l: +1-503-894-6022Toll Free: +1-800-792-5285UK: +44-845-528-1300India (Pune): +91-20-66346060Fax: [email protected]
Logo – https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/artificial-neural-network-market-to-reach-1-4-billion-by-2032-at-19-9-cagr-allied-market-research-301999358.html
New process definition capabilities in PIMS further enhance quality assurance and “right -first-time” initiatives for pharma manufacturers
WOKING, England, Nov. 28, 2023 /PRNewswire/ — IDBS unveils new process definition templates in its latest release, PIMS 5.1. Process definition templates enable pharma manufacturers to template process steps and quality specifications for faster process definition set-up and improved harmonization across the manufacturing teams to further enhance quality assurance (QA) and “right-first-time” initiatives.
Providing contextualized access to aggregated manufacturing data, PIMS offers a single source of data truth for efficient gathering, sharing and analysis of critical manufacturing process and quality data to support continued process verification (CPV), investigations and process optimization.
This release builds on recent PIMS’ process definition enhancements that added process definition versioning and approvals to help alleviate manual standard operating procedure (SOP) requirements and enhance QA for a more robust GxP environment.
PIMS’ customers report that these standardized process definition templates will reduce their manual process definition set-up and enable easy, harmonized site and product comparisons.
“Our customers recognize the value of being able to trace their process data over time, not only for tech transfer but also to help them learn from their historical data and optimize future process development,” says Pietro Forgione, General Manager at IDBS. “Having their critical process data in PIMS already gives them the assurance of data integrity and these new enhancements now make it even easier to complete QA and validation steps and move them closer to ‘right-first-time’ manufacturing.”
To learn more, register for the December 6 webinar here.
IDBS helps BioPharmaceutical organizations accelerate the discovery, development and manufacturing of the next generation of life-changing therapies that advance human health worldwide. From lab through manufacturing, IDBS leverages its 30+ years of experience working with a diverse list of customers – including 18 of the top 20 global BioPharma companies – and deep expertise in scientific informatics and process data management to tackle today’s most complex challenges.
Known for its signature IDBS E-WorkBook product, IDBS has extended solutions across the entire value chain for BioPharma Lifecycle Management (BPLM). Built on analytics-centric and cloud-native technology, IDBS Polar and Skyland PIMS platforms are powered by a digital data backbone to drive faster and smarter decisions in drug development and across the supply chain.
Learn more at idbs.com.
MEDIA ENQUIRIES e | [email protected]
Logo – https://mma.prnewswire.com/media/2007678/IDBS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/new-process-definition-capabilities-in-pims-further-enhance-quality-assurance-and-right–first-time-initiatives-for-pharma-manufacturers-301996766.html
- Cisco Doubles Down on Network Assurance with AWS
- Artificial Neural Network Market to Reach $1.4 Billion by 2032 at 19.9% CAGR: Allied Market Research
- New process definition capabilities in PIMS further enhance quality assurance and “right -first-time” initiatives for pharma manufacturers
- Industrial Control And Factory Automation Market size worth $ 259.3 Billion, Globally, by 2030 at 8.07% CAGR: Verified Market Research®
- Artificial Intelligence in BFSI Market to Reach $ 368.6 Billion, Globally, by 2032 at 32.5%% CAGR: Allied Market Research
- Structural Health Monitoring Sensors for Critical Infrastructure to Reach 22.9 Million Connections by 2030
- Kao Data Announces its Second, 10MW Harlow Data Centre is Now Live and Operational
- Five Cybersecurity Trends to Expect in 2024
- USE OF MALICIOUS WEB LINKS IN EMAILS HAS RISEN BY 144% IN 2023 – NEW HORNETSECURITY REPORT
- Starburst Expands Support for Building Interactive Applications on the Data Lake
- Clario’s New AI-Powered ECG Quality Score Tool Enhances Cardiac Safety Assessments
- Launch of Altair® RapidMiner® 2023 Platform Delivers Next-Generation Generative AI Capabilities
- BlackBerry Quarterly Global Threat Intelligence Report Shows 70 Percent Increase in Novel Malware Attacks
- Top AI experts share insights at HKUST-Greater Bay Area Association of Academicians symposium
- Bitget Announces Listing of Friend3, Supporting Social dApp Innovation
Artificial Intelligence5 days ago
ValueLabs Emerges as a Trailblazer in the Generative AI Space, Wins Prestigious Stevie International Business Awards® 2023
Artificial Intelligence5 days ago
Multiplex Assay Market to Reach $7.7 Billion, Globally, by 2032 at 7.8% CAGR: Allied Market Research
Artificial Intelligence5 days ago
Trillium Health Partners to become first in Canada to deploy AI in diagnostic imaging using Sectra Amplifier Services
Artificial Intelligence4 days ago
Isothermal Nucleic Acid Amplification Technology Market worth $8.83 Bn by 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
Artificial Intelligence5 days ago
RIVERSONG Expands Global Reach with Official Entry into Russian Market
Artificial Intelligence5 days ago
TECHNOLOGY MAGAZINE RELEASES TOP 100 CTOs LIST
Artificial Intelligence4 days ago
Jianpu Technology Inc. Reports Third Quarter 2023 Unaudited Financial Results
Artificial Intelligence5 days ago
Genpact Launches Artificial Intelligence Innovation Center in London, UK